Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | PPARD | Q03181 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 2/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679183 | 0.91 | LMNA (0.67) | LMNAPLA2G4BALOX15PTPN7PPARG | |
| SCHEMBL413254 | 0.87 | LMNA (0.81) | LMNAPLA2G4BALOX15PTPN7PPARG | |
| SCHEMBL715593 | 0.85 | ALDH1A1 (0.54) | — | |
| SCHEMBL5434776 | 0.85 | PLA2G4B (0.81) | LMNAPLA2G4BALOX15PTPN7PPARG | |
| SCHEMBL3159400 | 0.85 | LMNA (0.63) | LMNAPLA2G4BALOX15PTPN7PPARG | |
| SCHEMBL3169110 | 0.82 | PPARA (0.72) | LMNAALOX15PTPN7PPARGPPARA | |
| SCHEMBL3165108 | 0.81 | PPARA (0.74) | LMNAALOX15PPARGPPARAFFAR1 | |
| SCHEMBL17284878 | 0.80 | PPARA (0.77) | LMNAPLA2G4BALOX15PPARGPPARA | |
| SCHEMBL8928374 | 0.79 | PRSS1 (0.53) | — | |
| SCHEMBL15063356 | 0.79 | LMNA (0.74) | LMNAPLA2G4BALOX15PTPN7PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2094662-B1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC (JP) | 2012-04-11 | — | — | EP | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | LMNA 4586/4885PLA2G4B 2379/4885ALOX15 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.